Cornelius Gucfa, MD
Psychiatry · West Des Moines, IANPI 1942274626
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 27.4% of the total. Reporting peaked in 2019 at $747 and has fallen 95.6% since, to $33 in 2024.
Across 97 payments — averaging $10.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$275
- Otsuka America Pharmaceutical, Inc.$225
- Sunovion Pharmaceuticals Inc.$136
- Johnson & Johnson$102
- Alkermes, Inc.$58
- Lundbeck LLC$57
- plus $149 from 6 others
What the payments were for
- Food & beverage$94294%
- Education$606%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 44 | $275 |
| Otsuka America Pharmaceutical, Inc. | 21 | $225 |
| Sunovion Pharmaceuticals Inc. | 12 | $136 |
| Johnson & Johnson | 5 | $102 |
| Alkermes, Inc. | 3 | $58 |
| Lundbeck LLC | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $39 |
| Corium, LLC | 1 | $33 |
| Ironshore Pharmaceuticals Inc. | 2 | $29 |
| Bausch Health US, LLC | 1 | $22 |
| Shire North American Group Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$1,002 in reported general payments places this provider in the 75th percentile of 245 psychiatry providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 18 | $154,284 |
| AustedoDeutetrabenazine | 17 | $115,012 |
| Invega SustennaPaliperidone Palmitate | 22 | $62,901 |
| RexultiBrexpiprazole | 42 | $62,836 |
| Risperdal ConstaRisperidone Microspheres | 46 | $56,180 |
| VraylarCariprazine Hcl | 31 | $43,928 |
| AristadaAripiprazole Lauroxil | 14 | $42,994 |
| TrintellixVortioxetine Hydrobromide | 24 | $16,842 |
| Clozapine | 62 | $8,949 |
| ConcertaMethylphenidate Hcl | 17 | $6,712 |
| Quetiapine Fumarate | 333 | $6,203 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 162 | $6,163 |
| Aripiprazole | 225 | $6,001 |
| Bupropion XlBupropion Hcl | 335 | $5,666 |
| Lurasidone Hcl | 14 | $5,589 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta, Concerta | $102 | $125,79385 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $12 | $115,01217 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $225 | $62,83642 claims |
| AbbVieVraylar | $275 | $43,92831 claims |
| Alkermes, Inc.Aristada | $58 | $42,99414 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $39 | $21,31436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 245 psychiatry providers in Iowa.
Other psychiatry in West Des Moines
- Randall KavalierWest Des Moines$15K
- Charles JennischUrbandale$949K
- Manmohan SinghDes Moines$408K
- Jimmy MascaroOttumwa$361K
- Alan WhittersCedar Rapids$170K
- Donald BlackIowa City$19K
- William CoryellIowa City$18K
- Dwight SchroederCedar Rapids$13K
- Rodney DeanSioux City$11K
- Peggy NopoulosIowa City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.